Respiratory Tract Infection Therapeutics Market, By Infection Type (Viral, Bacterial and Fungal), By Drugs Class, By Disease Type, By End-Use, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2026-2033
|
Report ID
ANV5966
|
Published Date
September 2026
|
Pages
278
|
Industry
Healthcare
|
|
|
Base Year
2025
|
Historical Data
2019-2024
|
Delivery Timeline
24 Hour
|
REPORT HIGHLIGHT
Respiratory Tract Infection Therapeutics Market size was valued at USD 50,908.3 Million in 2025, expanding to a CAGR of 9.1% from 2026 to 2033.
The respiratory tract infection therapeutics comprises pharmaceutical products developed to prevent, manage, and treat infections affecting the upper and lower respiratory tract. The market encompasses therapies used for conditions such as common cold, sinusitis, pharyngitis, bronchitis, and pneumonia, as well as other bacterial, viral, and fungal respiratory infections.
Respiratory Tract Infection Therapeutics Market- Market Dynamics
Increasing prevalence of viral & bacterial respiratory infections and demand for next-gen anti-infective therapies are expected to propel market demand
The rising incidence of viral and bacterial respiratory infections is a key factor supporting the growth of the respiratory tract infection therapeutics market. Respiratory infections continue to account for a substantial share of physician consultations, emergency department visits, hospital admissions, and pharmaceutical consumption, creating sustained demand for effective treatment options. Diseases such as influenza, pneumonia, bronchitis, sinusitis, COVID-19, and respiratory syncytial virus (RSV) infections affect pediatric, adult, and elderly populations, resulting in recurring demand for symptomatic, antiviral, antibacterial, and supportive therapies. Lower respiratory tract infections represent a particularly significant area of treatment demand because severe infections, especially pneumonia, can lead to hospitalization, complications, and mortality. According to the WHO, pneumonia is an acute respiratory infection that can be caused by viruses, bacteria, or other pathogens, while antibiotics remain an important treatment option for bacterial pneumonia.
The growing prevalence of antimicrobial resistance (AMR) is creating significant demand for new and more effective therapies for respiratory tract infections. Resistance can reduce the effectiveness of established antibiotics, making infections more difficult to manage and increasing the need for treatments capable of addressing multidrug-resistant bacterial pathogens. This challenge is particularly important in cases of severe bacterial pneumonia and hospital-acquired respiratory infections, where resistant organisms can lead to prolonged hospitalization, treatment failure, and higher healthcare costs. According to the WHO, one in six laboratory-confirmed bacterial infections associated with common infections globally was resistant to antibiotic treatment in 2023, while resistance increased in more than 40% of monitored pathogen–antibiotic combinations between 2018 and 2023. These trends are encouraging pharmaceutical and biotechnology companies to invest in next-generation antibiotics.
Respiratory Tract Infection Therapeutics Market- Segmentation Analysis:
The Global Respiratory Tract Infection Therapeutics Market is segmented on the basis of Infection Type, Drugs Class, Disease Type, End-Use, and Region.
The market is divided into six categories based on Drugs Class: antibiotics, antiviral drugs, antifungal drugs, NSAIDs, analgesics, and others. Antibiotics constitute a major drugs class segment in the respiratory tract infection therapeutics market, supported by their continued use in the management of bacterial respiratory diseases. They are widely prescribed for infections such as pneumonia, bacterial sinusitis, bacterial bronchitis, etc.
Respiratory Tract Infection Therapeutics Market- Geographical Insights
North America represents a significant market for respiratory tract infection therapeutics, supported by its well-established pharmaceutical industry, high healthcare expenditure, advanced hospital infrastructure, and broad availability of branded and generic therapies. The region also benefits from strong demand for innovative antibiotics, antivirals, and other advanced anti-infective treatments, particularly for severe and drug-resistant respiratory infections. Asia-Pacific is emerging as an increasingly important market due to its large and growing population, high burden of respiratory infections. India launched its National Action Plan on Antimicrobial Resistance 2025–2029, incorporating a One Health approach. Europe maintains a well-developed respiratory therapeutics market, supported by strong pharmaceutical research capabilities, broad healthcare coverage, extensive hospital networks, and established antimicrobial stewardship initiatives. The region also serves as an important hub for the development and adoption of novel anti-infective therapies, with continued efforts to address antimicrobial resistance and improve treatment outcomes.
China Respiratory Tract Infection Therapeutics Market- Key Insights
China represents a significant and expanding market for respiratory tract infection therapeutics, supported by its large population, substantial burden of respiratory infections, expanding healthcare infrastructure, and growing pharmaceutical industry. The country has strong demand for antibiotics, antivirals, cough and cold medicines, bronchodilators, etc. China is also strengthening its domestic pharmaceutical and biotechnology capabilities, with local companies increasingly investing in innovative anti-infective drugs, respiratory therapies, and treatments for drug-resistant infections. In addition, the expansion of hospitals and specialty healthcare facilities, increasing diagnostic capabilities, and greater awareness of respiratory diseases are contributing to demand for targeted and evidence-based therapies.
Respiratory Tract Infection Therapeutics Market- Competitive Landscape:
The respiratory tract infection therapeutics market is competitive and diverse, with participation from multinational pharmaceutical companies, generic drug manufacturers, biotechnology firms, specialized anti-infective developers, and regional drug manufacturers. Companies are competing through new product development, expanded treatment indications, improved formulations, and therapies designed to address unmet clinical needs. The growing threat of antimicrobial resistance (AMR) is also encouraging investment in treatments targeting difficult-to-treat bacterial pathogens, while the persistent burden of influenza, COVID-19, and RSV infections continues to support the development of innovative antiviral therapies. Another notable market trend is the increasing focus on single-dose and short-duration treatment regimens, which can improve patient convenience, support treatment adherence, and reduce the overall burden of therapy.
Recent Developments:
- In May 2025, Basilea announced the U.S. commercial availability of Zevtera (ceftobiprole medocaril) through its partner Innoviva Specialty Therapeutics. The antibiotic is approved in the U.S. for the treatment of Staphylococcus aureus bacteremia in adults, strengthening the companies’ presence in the hospital anti-infective market.
- In August 2025, Innoviva Specialty Therapeutics continued to expand the U.S. commercialization of Zevtera under its exclusive distribution and licensing agreement with Basilea, supporting broader access to the antibiotic for the treatment of serious bacterial infections.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTICS MARKET KEY PLAYERS
- Pfizer Inc.
- GSK plc
- Sanofi
- Hoffmann-La Roche Ltd.
- Merck & Co., Inc.
- AstraZeneca plc
- AbbVie Inc.
- Boehringer Ingelheim
- Shionogi & Co., Ltd.
- Gilead Sciences, Inc.
- Viatris Inc.
- Teva Pharmaceutical Industries Ltd.
- Cipla Limited
- Basilea Pharmaceutica Ltd.
- Innoviva, Inc.
- Others
GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTICS MARKET, BY INFECTION TYPE- MARKET ANALYSIS, 2020-2033
- Viral
- Bacterial
- Fungal
GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTICS MARKET, BY DRUGS CLASS- MARKET ANALYSIS, 2020-2033
- Antibiotics
- Antiviral drugs
- Antifungal drugs
- NSAIDs
- Analgesics
- Others
GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTICS MARKET, BY DISEASE TYPE- MARKET ANALYSIS, 2020-2033
- Sinusitis
- Pharyngitis
- Laryngitis
- Bronchitis
- Pneumonia
- Influenza
- COVID-19
- Others
GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTICS MARKET, BY END-USE- MARKET ANALYSIS, 2020-2033
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTICS MARKET, BY REGION- MARKET ANALYSIS, 2020-2033
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Denmark
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Taiwan
- Vietnam
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Iran
- Qatar
- Rest of MEA
TABLE OF CONTENTS
1. Respiratory Tract Infection Therapeutics Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.2. Competitive Insights
3. Respiratory Tract Infection Therapeutics Key Market Trends
3.1. Respiratory Tract Infection Therapeutics Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Respiratory Tract Infection Therapeutics Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Respiratory Tract Infection Therapeutics Market Opportunities
3.4. Respiratory Tract Infection Therapeutics Market Future Trends
4. Respiratory Tract Infection Therapeutics Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Respiratory Tract Infection Therapeutics Market: Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. Respiratory Tract Infection Therapeutics Market Landscape
6.1. Respiratory Tract Infection Therapeutics Market Share Analysis, 2025
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Respiratory Tract Infection Therapeutics Market – By Infection Type
7.1. Overview
7.1.1. Segment Share Analysis, By Infection Type, 2025 & 2033 (%)
7.1.2. Viral
7.1.3. Bacterial
7.1.4. Fungal
8. Respiratory Tract Infection Therapeutics Market – By Drugs Class
8.1. Overview
8.1.1. Segment Share Analysis, By Drugs Class, 2025 & 2033 (%)
8.1.2. Antibiotics
8.1.3. Antiviral drugs
8.1.4. Antifungal drugs
8.1.5. NSAIDs
8.1.6. Analgesics
8.1.7. Others
9. Respiratory Tract Infection Therapeutics Market – By Disease Type
9.1. Overview
9.1.1. Segment Share Analysis, By Disease Type, 2025 & 2033 (%)
9.1.2. Sinusitis
9.1.3. Pharyngitis
9.1.4. Laryngitis
9.1.5. Bronchitis
9.1.6. Pneumonia
9.1.7. Influenza
9.1.8. COVID-19
9.1.9. Others
10. Respiratory Tract Infection Therapeutics Market – By End-Use
10.1. Overview
10.1.1. Segment Share Analysis, By End-Use, 2025 & 2033 (%)
10.1.2. Hospital Pharmacies
10.1.3. Retail Pharmacies
10.1.4. Online Pharmacies
10.1.5. Others
11. Respiratory Tract Infection Therapeutics Market– By Geography
11.1. Introduction
11.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
11.2. North America
11.2.1. Overview
11.2.2. Respiratory Tract Infection Therapeutics Key Manufacturers in North America
11.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.2.4. North America Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.2.5. North America Market Size and Forecast, By Drugs Class, 2020 - 2033 (US$ Million)
11.2.6. North America Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.2.7. North America Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.2.8. U.S.
11.2.8.1. Overview
11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.2.8.3. U.S. Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.2.8.4. U.S. Market Size and Forecast, By Drugs Class, 2020 - 2033 (US$ Million)
11.2.8.5. U.S. Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.2.8.6. U.S. Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.2.9. Canada
11.2.9.1. Overview
11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.2.9.3. Canada Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.2.9.4. Canada Market Size and Forecast, By Drugs Class, 2020 - 2033 (US$ Million)
11.2.9.5. Canada Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.2.9.6. Canada Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.3. Europe
11.3.1. Overview
11.3.2. Respiratory Tract Infection Therapeutics Key Manufacturers in Europe
11.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.3.4. Europe Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.3.5. Europe Market Size and Forecast, By Drugs Class, 2020 - 2033 (US$ Million)
11.3.6. Europe Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.3.7. Europe Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.3.8. Germany
11.3.8.1. Overview
11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.8.3. Germany Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.3.8.4. Germany Market Size and Forecast, By Drugs Class, 2020 - 2033 (US$ Million)
11.3.8.5. Germany Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.3.8.6. Germany Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.3.9. UK
11.3.9.1. Overview
11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.9.3. UK Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.3.9.4. UK Market Size and Forecast, By Drugs Class, 2020 - 2033 (US$ Million)
11.3.9.5. UK Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.3.9.6. UK Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.3.10. France
11.3.10.1. Overview
11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.10.3. France Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.3.10.4. France Market Size and Forecast, By Drugs Class, 2020 - 2033 (US$ Million)
11.3.10.5. France Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.3.10.6. France Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.3.11. Italy
11.3.11.1. Overview
11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.11.3. Italy Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.3.11.4. Italy Market Size and Forecast, By Drugs Class, 2020 - 2033 (US$ Million)
11.3.11.5. Italy Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.3.11.6. Italy Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.3.12. Spain
11.3.12.1. Overview
11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.12.3. Spain Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.3.12.4. Spain Market Size and Forecast, By Drugs Class, 2020 - 2033 (US$ Million)
11.3.12.5. Spain Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.3.12.6. Spain Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.3.13. The Netherlands
11.3.13.1. Overview
11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.13.3. The Netherlands Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.3.13.4. The Netherlands Market Size and Forecast, By Drugs Class, 2020 - 2033 (US$ Million)
11.3.13.5. The Netherlands Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.3.13.6. The Netherlands Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.3.14. Sweden
11.3.14.1. Overview
11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.14.3. Sweden Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.3.14.4. Sweden Market Size and Forecast, By Drugs Class, 2020 - 2033 (US$ Million)
11.3.14.5. Sweden Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.3.14.6. Sweden Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.3.15. Russia
11.3.15.1. Overview
11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.15.3. Russia Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.3.15.4. Russia Market Size and Forecast, By Drugs Class, 2020 - 2033 (US$ Million)
11.3.15.5. Russia Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.3.15.6. Russia Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.3.16. Poland
11.3.16.1. Overview
11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.16.3. Poland Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.3.16.4. Poland Market Size and Forecast, By Drugs Class, 2020 - 2033 (US$ Million)
11.3.16.5. Poland Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.3.16.6. Poland Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.3.17. Rest of Europe
11.3.17.1. Overview
11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.17.3. Rest of the Europe Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.3.17.4. Rest of the Europe Market Size and Forecast, By Drugs Class, 2020 - 2033 (US$ Million)
11.3.17.5. Rest of the Europe Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.3.17.6. Rest of the Europe Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.4. Asia Pacific (APAC)
11.4.1. Overview
11.4.2. Respiratory Tract Infection Therapeutics Key Manufacturers in Asia Pacific
11.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.4.4. APAC Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.4.5. APAC Market Size and Forecast, By Drugs Class, 2020 - 2033 (US$ Million)
11.4.6. APAC Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.4.7. APAC Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.4.8. China
11.4.8.1. Overview
11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.8.3. China Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.4.8.4. China Market Size and Forecast, By Drugs Class, 2020 - 2033 (US$ Million)
11.4.8.5. China Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.4.8.6. China Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.4.9. India
11.4.9.1. Overview
11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.9.3. India Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.4.9.4. India Market Size and Forecast, By Drugs Class, 2020 - 2033 (US$ Million)
11.4.9.5. India Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.4.9.6. India Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.4.10. Japan
11.4.10.1. Overview
11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.10.3. Japan Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.4.10.4. Japan Market Size and Forecast, By Drugs Class, 2020 - 2033 (US$ Million)
11.4.10.5. Japan Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.4.10.6. Japan Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.4.11. South Korea
11.4.11.1. Overview
11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.11.3. South Korea Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.4.11.4. South Korea Market Size and Forecast, By Drugs Class, 2020 - 2033 (US$ Million)
11.4.11.5. South Korea Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.4.11.6. South Korea Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.4.12. Australia
11.4.12.1. Overview
11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.12.3. Australia Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.4.12.4. Australia Market Size and Forecast, By Drugs Class, 2020 - 2033 (US$ Million)
11.4.12.5. Australia Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.4.12.6. Australia Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.4.13. Indonesia
11.4.13.1. Overview
11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.13.3. Indonesia Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.4.13.4. Indonesia Market Size and Forecast, By Drugs Class, 2020 - 2033 (US$ Million)
11.4.13.5. Indonesia Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.4.13.6. Indonesia Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.4.14. Thailand
11.4.14.1. Overview
11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.14.3. Thailand Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.4.14.4. Thailand Market Size and Forecast, By Drugs Class, 2020 - 2033 (US$ Million)
11.4.14.5. Thailand Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.4.14.6. Thailand Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.4.15. Philippines
11.4.15.1. Overview
11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.15.3. Philippines Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.4.15.4. Philippines Market Size and Forecast, By Drugs Class, 2020 - 2033 (US$ Million)
11.4.15.5. Philippines Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.4.15.6. Philippines Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.4.16. Rest of APAC
11.4.16.1. Overview
11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.16.3. Rest of APAC Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.4.16.4. Rest of APAC Market Size and Forecast, By Drugs Class, 2020 - 2033 (US$ Million)
11.4.16.5. Rest of APAC Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.4.16.6. Rest of APAC Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.5. Latin America (LATAM)
11.5.1. Overview
11.5.2. Respiratory Tract Infection Therapeutics Key Manufacturers in Latin America
11.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.5.4. LATAM Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.5.5. LATAM Market Size and Forecast, By Drugs Class, 2020 - 2033 (US$ Million)
11.5.6. LATAM Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.5.7. LATAM Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.5.8. Brazil
11.5.8.1. Overview
11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.8.3. Brazil Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.5.8.4. Brazil Market Size and Forecast, By Drugs Class, 2020 - 2033 (US$ Million)
11.5.8.5. Brazil Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.5.8.6. Brazil Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.5.9. Mexico
11.5.9.1. Overview
11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.9.3. Mexico Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.5.9.4. Mexico Market Size and Forecast, By Drugs Class, 2020 - 2033 (US$ Million)
11.5.9.5. Mexico Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.5.9.6. Mexico Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.5.10. Argentina
11.5.10.1. Overview
11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.10.3. Argentina Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.5.10.4. Argentina Market Size and Forecast, By Drugs Class, 2020 - 2033 (US$ Million)
11.5.10.5. Argentina Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.5.10.6. Argentina Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.5.11. Colombia
11.5.11.1. Overview
11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.11.3. Colombia Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.5.11.4. Colombia Market Size and Forecast, By Drugs Class, 2020 - 2033 (US$ Million)
11.5.11.5. Colombia Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.5.11.6. Colombia Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.5.12. Rest of LATAM
11.5.12.1. Overview
11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.12.3. Rest of LATAM Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.5.12.4. Rest of LATAM Market Size and Forecast, By Drugs Class, 2020 - 2033 (US$ Million)
11.5.12.5. Rest of LATAM Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.5.12.6. Rest of LATAM Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.6. Middle East and Africa (MEA)
11.6.1. Overview
11.6.2. Respiratory Tract Infection Therapeutics Key Manufacturers in Middle East and Africa
11.6.3. MEA Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.6.4. MEA Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.6.5. MEA Market Size and Forecast, By Drugs Class, 2020 - 2033 (US$ Million)
11.6.6. MEA Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.6.7. MEA Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.6.8. Saudi Arabia
11.6.8.1. Overview
11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.8.3. Saudi Arabia Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.6.8.4. Saudi Arabia Market Size and Forecast, By Drugs Class, 2020 - 2033 (US$ Million)
11.6.8.5. Saudi Arabia Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.6.8.6. Saudi Arabia Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.6.9. United Arab Emirates
11.6.9.1. Overview
11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.9.3. United Arab Emirates Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.6.9.4. United Arab Emirates Market Size and Forecast, By Drugs Class, 2020 - 2033 (US$ Million)
11.6.9.5. United Arab Emirates Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.6.9.6. United Arab Emirates Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.6.10. Israel
11.6.10.1. Overview
11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.10.3. Israel Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.6.10.4. Israel Market Size and Forecast, By Drugs Class, 2020 - 2033 (US$ Million)
11.6.10.5. Israel Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.6.10.6. Israel Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.6.11. Turkey
11.6.11.1. Overview
11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.11.3. Turkey Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.6.11.4. Turkey Market Size and Forecast, By Drugs Class, 2020 - 2033 (US$ Million)
11.6.11.5. Turkey Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.6.11.6. Turkey Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.6.12. Algeria
11.6.12.1. Overview
11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.12.3. Algeria Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.6.12.4. Algeria Market Size and Forecast, By Drugs Class, 2020 - 2033 (US$ Million)
11.6.12.5. Algeria Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.6.12.6. Algeria Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.6.13. Egypt
11.6.13.1. Overview
11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.13.3. Egypt Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.6.13.4. Egypt Market Size and Forecast, By Drugs Class, 2020 - 2033 (US$ Million)
11.6.13.5. Egypt Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.6.13.6. Egypt Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.6.14. Rest of MEA
11.6.14.1. Overview
11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.14.3. Rest of MEA Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.6.14.4. Rest of MEA Market Size and Forecast, By Drugs Class, 2020 - 2033 (US$ Million)
11.6.14.5. Rest of MEA Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.6.14.6. Rest of MEA Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
12. Key Vendor Analysis- Respiratory Tract Infection Therapeutics Industry
12.1. Competitive Dashboard
12.1.1. Competitive Benchmarking
12.1.2. Competitive Positioning
12.2. Company Profiles
12.2.1. Pfizer Inc.
12.2.2. GSK plc
12.2.3. Sanofi
12.2.4. F. Hoffmann-La Roche Ltd.
12.2.5. Merck & Co., Inc.
12.2.6. AstraZeneca plc
12.2.7. AbbVie Inc.
12.2.8. Boehringer Ingelheim
12.2.9. Shionogi & Co., Ltd.
12.2.10. Gilead Sciences, Inc.
12.2.11. Viatris Inc.
12.2.12. Teva Pharmaceutical Industries Ltd.
12.2.13. Cipla Limited
12.2.14. Basilea Pharmaceutica Ltd.
12.2.15. Innoviva, Inc.
12.2.16. Others
13. 360 Degree AnalystView
14. Appendix
14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTICS MARKET KEY PLAYERS
- Pfizer Inc.
- GSK plc
- Sanofi
- Hoffmann-La Roche Ltd.
- Merck & Co., Inc.
- AstraZeneca plc
- AbbVie Inc.
- Boehringer Ingelheim
- Shionogi & Co., Ltd.
- Gilead Sciences, Inc.
- Viatris Inc.
- Teva Pharmaceutical Industries Ltd.
- Cipla Limited
- Basilea Pharmaceutica Ltd.
- Innoviva, Inc.
- Others
GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTICS MARKET, BY INFECTION TYPE- MARKET ANALYSIS, 2020-2033
- Viral
- Bacterial
- Fungal
GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTICS MARKET, BY DRUGS CLASS- MARKET ANALYSIS, 2020-2033
- Antibiotics
- Antiviral drugs
- Antifungal drugs
- NSAIDs
- Analgesics
- Others
GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTICS MARKET, BY DISEASE TYPE- MARKET ANALYSIS, 2020-2033
- Sinusitis
- Pharyngitis
- Laryngitis
- Bronchitis
- Pneumonia
- Influenza
- COVID-19
- Others
GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTICS MARKET, BY END-USE- MARKET ANALYSIS, 2020-2033
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTICS MARKET, BY REGION- MARKET ANALYSIS, 2020-2033
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Denmark
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Taiwan
- Vietnam
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Iran
- Qatar
- Rest of MEA
Related Reports
Credibility and Certifications
Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.
ISO 9001:2015
ESOMAR Corporate
GDPR Compliance
D-U-N-S Registered
BBB Accreditation
MRS
